We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+31.31%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.59B
AUM Growth
+$94.3M
Cap. Flow
-$331M
Cap. Flow %
-12.8%
Top 10 Hldgs %
60.43%
Holding
115
New
13
Increased
19
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$58.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.9M
3
PYPL icon
PayPal
PYPL
+$20.8M
4
ARGX icon
argenx
ARGX
+$20.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$12.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$70M
2
NVDA icon
NVIDIA
NVDA
+$34.8M
3
AVTR icon
Avantor
AVTR
+$19.9M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$17M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.99%
2 Consumer Discretionary 25.71%
3 Communication Services 1.46%
4 Technology 1.19%
5 Financials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
26
DELISTED
Aravive, Inc. Common Stock
ARAV
$18.5M 0.71%
1,350,000
+950,000
+238% +$8.4M
KYNB
27
Kyntra Bio
KYNB
$28.1M
$17.2M 0.66%
16,000
+8,800
+122% +$8.98M
STNE icon
28
StoneCo
STNE
$2.64B
$16M 0.62%
400,000
+100,000
+33% +$3.66M
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$15.6M 0.6%
250,000
-250,000
-50% -$11.9M
UBER icon
30
Uber
UBER
$143B
$14.9M 0.57%
500,000
– –
AAL icon
31
CALL
American Airlines Group
AAL
$9.97B
$14.3M 0.55%
500,000
– –
ASND icon
32
Ascendis Pharma A/S
ASND
$16.6B
$13.9M 0.54%
100,000
-50,000
-33% -$5.55M
IOVA icon
33
Iovance Biotherapeutics
IOVA
$2.02B
$13.8M 0.53%
500,000
-200,000
-29% -$4.55M
TCDA
34
DELISTED
Tricida, Inc. Common Stock
TCDA
$13.6M 0.52%
360,000
– –
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
$13.5M 0.52%
350,000
+41,474
+13% +$971K
PRQR icon
36
ProQR Therapeutics
PRQR
$243M
$12.9M 0.5%
1,300,000
– –
HARP
37
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$12.6M 0.49%
+85,000
New +$12.9M
YMAB
38
DELISTED
Y-mAbs Therapeutics
YMAB
$12.5M 0.48%
400,000
– –
HOOK
39
DELISTED
HOOKIPA Pharma
HOOK
$12.3M 0.47%
100,499
-12,963
-11% -$1.1M
ALBO
40
DELISTED
Albireo Pharma Inc
ALBO
$11.4M 0.44%
450,200
– –
DRNA
41
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$11M 0.43%
500,000
-500,000
-50% -$10.1M
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$10.8M 0.42%
150,000
– –
NKTR icon
43
CALL
Nektar Therapeutics
NKTR
$2.29B
$10.8M 0.42%
33,333
-6,667
-17% -$1.93M
CLVS
44
DELISTED
Clovis Oncology, Inc.
CLVS
$10.4M 0.4%
1,000,000
+500,000
+100% +$3.64M
RETA
45
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.2M 0.39%
+50,000
New +$9.12M
AGEN
46
Agenus
AGEN
$277M
$10.2M 0.39%
127,375
– –
AXDX
47
DELISTED
Accelerate Diagnostics
AXDX
$10.1M 0.39%
60,000
+10,000
+20% +$1.65M
MRNA icon
48
CALL
Moderna
MRNA
$21.7B
$9.78M 0.38%
500,000
– –
BLUE
49
DELISTED
bluebird bio
BLUE
$8.78M 0.34%
7,720
– –
INCY icon
50
CALL
Incyte
INCY
$25.2B
$8.73M 0.34%
100,000
-150,000
-60% -$12.8M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2019 Portfolio in Review

As of Q4 2019, Artal Group held 115 positions worth $2.59B, up 3.8% from $2.49B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group withdrew a net $331M in Q4 2019, closing 19 positions and reducing 20 holdings. Its most notable exit was Medicines Co, an estimated $70M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, Artal Group opened a new position in BioNTech worth $89M.

  • Artal Group's largest Q4 2019 buy was BioNTech: 2,628,130 shares worth $89M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q4 2019, an estimated $29.9M increase.
  • Artal Group's biggest Q4 2019 reduction was Avantor, cutting an estimated $19.9M.
  • Artal Group fully exited Medicines Co in Q4 2019, selling an estimated $70M.
  • Artal Group's ten largest holdings make up 60% of its $2.59B portfolio in Q4 2019.
  • Artal Group opened 13 new positions and closed 19 in Q4 2019.
  • Artal Group's portfolio value rose 3.8% quarter-over-quarter to $2.59B.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.